These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 30703461)

  • 1. Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States.
    Feldman SR; Regnier SA; Chirilov A; Hey F; Gilloteau I; Cella D
    J Am Acad Dermatol; 2019 Jun; 80(6):1650-1657. PubMed ID: 30703461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing preferences for outcomes of psoriasis treatments among patients and dermatologists in the U.K.: results from a discrete-choice experiment.
    Gonzalez JM; Johnson FR; McAteer H; Posner J; Mughal F
    Br J Dermatol; 2017 Mar; 176(3):777-785. PubMed ID: 27292093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR).
    Mahil SK; Wilson N; Dand N; Reynolds NJ; Griffiths CEM; Emsley R; Marsden A; Evans I; Warren RB; Stocken D; Barker JN; Burden AD; Smith CH;
    Br J Dermatol; 2020 May; 182(5):1158-1166. PubMed ID: 31286471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tradeoffs and decision-making in moderate to severe psoriasis for oral versus injectable treatments: data from patients and dermatologists in Australia.
    Smith SD; Fifer S; Edwards M; Walter A; Zhong Y; Zhuo J; West B; Spelman L
    J Dermatolog Treat; 2024 Dec; 35(1):2339440. PubMed ID: 39079697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining and treating moderate plaque psoriasis: a dermatologist survey.
    Knuckles MLF; Levi E; Soung J
    J Dermatolog Treat; 2018 Nov; 29(7):658-663. PubMed ID: 29502473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey.
    van de Kerkhof PC; Reich K; Kavanaugh A; Bachelez H; Barker J; Girolomoni G; Langley RG; Paul CF; Puig L; Lebwohl MG
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):2002-10. PubMed ID: 25885420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
    Al-Mutairi N; Nour T
    Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient preference for biologic treatments of psoriasis in Japan.
    Tada Y; Ishii K; Kimura J; Hanada K; Kawaguchi I
    J Dermatol; 2019 Jun; 46(6):466-477. PubMed ID: 30985030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying the biologic closest to the ideal to treat chronic plaque psoriasis in different clinical scenarios: using a pilot multi-attribute decision model as a decision-support aid.
    Guibal F; Iversen L; Puig L; Strohal R; Williams P
    Curr Med Res Opin; 2009 Dec; 25(12):2835-43. PubMed ID: 19916728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Moderate to Severe Psoriasis in Routine Clinical Practice in Spanish Hospitals.
    López-Estebaranz JL; de la Cueva-Dobao P; de la Torre Fraga C; Galán Gutiérrez M; González Guerra E; Mollet Sánchez J; Belinchón Romero I
    Actas Dermosifiliogr (Engl Ed); 2018 Sep; 109(7):631-642. PubMed ID: 29891209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients' and Physicians' Preferences for Systemic Psoriasis Treatments: A Nationwide Comparative Discrete Choice Experiment (PsoCompare).
    Schaarschmidt ML; Herr R; Gutknecht M; Wroblewska K; Gerdes S; Sticherling M; Augustin M; Peitsch WK
    Acta Derm Venereol; 2018 Feb; 98(2):200-205. PubMed ID: 29110022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study.
    Loft ND; Egeberg A; Rasmussen MK; Bryld LE; Gniadecki R; Dam TN; Iversen L; Skov L
    Acta Derm Venereol; 2019 Dec; 99(13):1224-1230. PubMed ID: 31580465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of childhood psoriasis in France. A national survey among general practitioners, pediatricians, and dermatologists.
    Mahé E; Bursztejn AC; Phan A; Corgibet F; Beauchet A
    Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29193624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On clinical thresholds, clinical equivalents and indirect comparisons of biological treatments for moderate-to-severe psoriasis.
    Puig L
    J Clin Pharm Ther; 2015 Apr; 40(2):131-4. PubMed ID: 25627250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
    Papp KA; Gordon KB; Langley RG; Lebwohl MG; Gottlieb AB; Rastogi S; Pillai R; Israel RJ
    Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Satisfaction with current psoriasis treatment: misalignment between physician and patient perceptions.
    Korman NJ; Zhao Y; Pike J; Roberts J; Sullivan E; Kemhus M
    Dermatol Online J; 2016 Jul; 22(7):. PubMed ID: 27617714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dermatologists' Perspectives on Defining Moderate Psoriasis: The Canadian Moderate Psoriasis Survey.
    Gooderham M; Papp K; Albrecht L; Grewal P; Gaudreau AJ
    J Drugs Dermatol; 2021 Feb; 20(2):126-132. PubMed ID: 33538558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moderate Psoriasis: A Proposed Definition.
    Llamas-Velasco M; de la Cueva P; Notario J; Martínez-Pilar L; Martorell A; Moreno-Ramírez D
    Actas Dermosifiliogr; 2017 Dec; 108(10):911-917. PubMed ID: 28823420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study.
    Chaptini C; Quinn S; Marshman G
    Australas J Dermatol; 2016 Aug; 57(3):e72-5. PubMed ID: 26010650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.